Antioxidant and Immunity Activities of Fufang Kushen Injection Liquid

Zhou, Siying; Zhang, Ruili; Xu, Yunfeng; Bi, Tienan

doi:10.3390/molecules17066481

Cited by 24 publications

(18 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…its wide spectrum of pharmacological actions including antiinflammatory, immune-inhibitory, anti-fibrotic, antiarrhythmic, anti-tumor and diuretic activities (Xu et al, 2011;Zhou et al, 2012;Zhi, 2009).…”

Section: Introductionmentioning

confidence: 99%

Investigating herb–herb interactions: The potential attenuated toxicity mechanism of the combined use of Glycyrrhizae radix et rhizoma (Gancao) and Sophorae flavescentis radix (Kushen)

Shi

Tang

Dang

et al. 2015

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Investigating herb–herb interactions: The potential attenuated toxicity mechanism of the combined use of Glycyrrhizae radix et rhizoma (Gancao) and Sophorae flavescentis radix (Kushen)

Shi

Tang

Dang

et al. 2015

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…The main compounds in CKI are matrine, oxymatrine and sophoridine. These compounds are associated with liver protection and the treatment of viral hepatitis and HCC in China ( Zhou et al, 2012 ; Wang et al, 2015 ; Parvez et al, 2016 ). The combination of CKI and TACE may increase the therapeutic efficacy of unresectable HCC treatment.…”

Section: Introductionmentioning

confidence: 99%

The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis

Wang

et al. 2016

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Compound Kushen Injection (CKI) is a Chinese patent medicine approved by the China Food and Drug Administration for the treatment of various types of solid tumors. CKI, combined with transarterial chemoembolization (TACE), is believed to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC). We report an updated and extended meta-analysis with detailed outcomes of both the efficacy and adverse events (AEs) of CKI combined with TACE therapy.Materials and methods: Electronic databases, including PubMed, Embase, the Cochrane Library, the Chinese Biomedical Database (CBM), Wanfang, the VIP medicine information system (VMIS) and the China National Knowledge Infrastructure (CNKI), were examined for relevant articles before November 13, 2015. An odds ratio (OR) was used to estimate tumor response (TR), Karnofsky Performance Scale (KPS) improvement, Child-Pugh (CP) improvement, survival rate (SR) and AEs. A publication bias and a subgroup analysis were also assessed.Results: Eighteen studies, with a total of 1,338 HCC patients who met the criteria for the meta-analysis, were included. TR, KPS improvement and CP improvement were significantly enhanced for the combination therapy compared to TACE alone (OR = 1.84, 95% CI: [1.46, 2.33], P < 0.00001; OR = 2.37, 95% CI: [1.76, 3.18], P < 0.00001; OR = 1.81, 95% CI: [1.08, 3.03], P = 0.02, respectively). The combination therapy was associated with an improvement in 1-year and 2-year SRs but not an improved 3-year SR (OR = 2.40; 95% CI: [1.59, 3.62], P < 0.0001; OR = 2.49, 95% CI: [1.24, 5.00], P = 0.01; OR = 2.49, 95% CI: [0.94, 6.61], P = 0.07, respectively). A safety analysis indicated that AEs (including nausea/vomiting, fever, hepatalgia, increased transaminase, increased bilirubin and leukopenia) were reduced for the combination treatment compared to TACE alone.Conclusion: The combination treatment of TACE and CKI was associated with improved TR, KPS and CP improvement and improved 1- and 2-year SRs in patients with unresectable HCC. The 3-year SR was not improved. The combination therapy resulted in a reduction in AEs. The findings of this study should be interpreted with caution because of the small sample size and study limitations.

show abstract

“…In addition, it has synergistic and attenuation actions with anti-tumor agents in H22 and S180 cancer cells. The anti-tumor mechanisms of CKI may include: (1) increased protein expression of p16; (2) reduced unmethylated state of the p16 gene; (3) inhibited VEGF and MVD expression in neoplastic tissues; (4) decreased microvessel density [11,27,28] . Zhou et al [28] investigated the effects of CKI on gastric immunity and oxidantantioxidant status during N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastric carcinogenesis.…”

Section: Studies On Compound Kushen Injectionmentioning

confidence: 99%

“…The anti-tumor mechanisms of CKI may include: (1) increased protein expression of p16; (2) reduced unmethylated state of the p16 gene; (3) inhibited VEGF and MVD expression in neoplastic tissues; (4) decreased microvessel density [11,27,28] . Zhou et al [28] investigated the effects of CKI on gastric immunity and oxidantantioxidant status during N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastric carcinogenesis. They found that the administration of CKI significantly enhanced serum IgA, IgG, IgM, IL-2, IL-4, and IL-10 levels; decreased serum IL-6 and TNF-α levels; lowered the levels of lipid peroxides; and enhanced glutathione (GSH) levels and activities of GSHdependent enzymes.…”

Section: Studies On Compound Kushen Injectionmentioning

confidence: 99%

Anti-tumor activities of active ingredients in Compound Kushen Injection

Wang¹,

et al. 2015

View full text Add to dashboard Cite

Kushen (Radix Sophorae Flavescentis) has a long history of use for the treatment of tumors, inflammation and other diseases in traditional Chinese medicine. Compound Kushen Injection (CKI) is a mixture of natural compounds extracted from Kushen and Baituling (Rhizoma Smilacis Glabrae). The main principles of CKI are matrine (MT) and oxymatrine (OMT) that exhibit a variety of pharmacological activities, including anti-inflammatory, anti-allergic, anti-viral, anti-fibrotic and cardiovascular protective effects. Recent evidence shows that these compounds also produce anti-cancer actions, such as inhibiting cancer cell proliferation, inducing cell cycle arrest, accelerating apoptosis, restraining angiogenesis, inducing cell differentiation, inhibiting cancer metastasis and invasion, reversing multidrug resistance, and preventing or reducing chemotherapy-and/or radiotherapy-induced toxicity when combined with chemotherapeutic drugs. In this review, we summarize recent progress in studying the anti-cancer activities of MT, OMT and CKI and their potential molecular targets, which provide clues and references for further study.

show abstract

Antioxidant and Immunity Activities of Fufang Kushen Injection Liquid

Cited by 24 publications

References 46 publications

Investigating herb–herb interactions: The potential attenuated toxicity mechanism of the combined use of Glycyrrhizae radix et rhizoma (Gancao) and Sophorae flavescentis radix (Kushen)

Investigating herb–herb interactions: The potential attenuated toxicity mechanism of the combined use of Glycyrrhizae radix et rhizoma (Gancao) and Sophorae flavescentis radix (Kushen)

The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis

Anti-tumor activities of active ingredients in Compound Kushen Injection

Contact Info

Product

Resources

About